TY - JOUR
T1 - Differentiation of human induced pluripotent stem cells into functional enterocyte-like cells using a simple method
AU - Iwao, Takahiro
AU - Toyota, Masashi
AU - Miyagawa, Yoshitaka
AU - Okita, Hajime
AU - Kiyokawa, Nobutaka
AU - Akutsu, Hidenori
AU - Umezawa, Akihiro
AU - Nagata, Kiyoshi
AU - Matsunaga, Tamihide
N1 - Funding Information:
Received January 25, 2013; Accepted June 21, 2013 J-STAGE Advance Published Date: July 2, 2013, doi:10.2133/dmpk.DMPK-13-RG-005 *To whom correspondence should be addressed: Tamihide MATSUNAGA, Ph.D., Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan. Tel. ©81-52-836-3751, Fax. ©81-52-836-3751, E-mail: tmatsu@phar.nagoya-cu.ac.jp. This work was supported, in part, by Grants-in-Aid from the Japan Society for the Promotion of Science (23390036), by a National Grant-in-Aid from Japanese Ministry of Health, Labor, and Welfare (H22-003), and by a Grant-in-Aid for Research in Nagoya City University.
PY - 2014
Y1 - 2014
N2 - Human induced pluripotent stem (iPS) cells were differentiated into the endoderm using activin A and were then treated with fibroblast growth factor 2 (FGF2) for differentiation into intestinal stem cell-like cells. These immature cells were then differentiated into enterocyte-like cells using epidermal growth factor (EGF) in 2% fetal bovine serum (FBS). At the early stage of differentiation, mRNA expression of caudal type homeobox 2 (CDX2), a major transcription factor related to intestinal development and differentiation, and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), an intestinal stem cell marker, was markedly increased by treatment with FGF2. When cells were cultured in medium containing EGF and a low concentration of FBS, mRNAs of specific markers of intestinal epithelial cells, including sucrase-isomaltase, the intestinal oligopeptide transporter SLC15A1/peptide transporter 1 (PEPT1), and the major metabolizing enzyme CYP3A4, were expressed. In addition, sucraseisomaltase protein expression and uptake of β-Ala-Lys-N-7-amino-4-methylcoumarin-3-acetic acid (β-Ala-Lys-AMCA), a fluorescence-labeled substrate of the oligopeptide transporter, were detected. These results demonstrate a simple and direct method for differentiating human iPS cells into functional enterocyte-like cells.
AB - Human induced pluripotent stem (iPS) cells were differentiated into the endoderm using activin A and were then treated with fibroblast growth factor 2 (FGF2) for differentiation into intestinal stem cell-like cells. These immature cells were then differentiated into enterocyte-like cells using epidermal growth factor (EGF) in 2% fetal bovine serum (FBS). At the early stage of differentiation, mRNA expression of caudal type homeobox 2 (CDX2), a major transcription factor related to intestinal development and differentiation, and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), an intestinal stem cell marker, was markedly increased by treatment with FGF2. When cells were cultured in medium containing EGF and a low concentration of FBS, mRNAs of specific markers of intestinal epithelial cells, including sucrase-isomaltase, the intestinal oligopeptide transporter SLC15A1/peptide transporter 1 (PEPT1), and the major metabolizing enzyme CYP3A4, were expressed. In addition, sucraseisomaltase protein expression and uptake of β-Ala-Lys-N-7-amino-4-methylcoumarin-3-acetic acid (β-Ala-Lys-AMCA), a fluorescence-labeled substrate of the oligopeptide transporter, were detected. These results demonstrate a simple and direct method for differentiating human iPS cells into functional enterocyte-like cells.
KW - Drug metabolizing enzymes
KW - Drug transporters
KW - Enterocytes
KW - Human iPS cells
KW - Intestinal differentiation
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=84898488352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898488352&partnerID=8YFLogxK
U2 - 10.2133/dmpk.DMPK-13-RG-005
DO - 10.2133/dmpk.DMPK-13-RG-005
M3 - Article
C2 - 23822979
AN - SCOPUS:84898488352
SN - 1347-4367
VL - 29
SP - 44
EP - 51
JO - Drug Metabolism And Pharmacokinetics
JF - Drug Metabolism And Pharmacokinetics
IS - 1
ER -